Backed By Science

They were randomized to receive 1 of 3 treatments: 25 mg or 50 mg of sildenafil or placebo.14 A protocol-specified trial involved premenopausal or postmenopausal women with sexual arousal disorder without concomitant hypoactive sexual desire disorder. Women with low baseline estrogen and androgen levels received therapy, so their hormone levels would be within the range of normal therapy and were randomly assigned to receive either a flexible dose of between 25 mg and 100 mg of sildenafil or placebo.15 In a third trial, postmenopausal women receiving estrogen hormone therapy and who had acquired sexual arousal disorder and impaired orgasm found that a single dose of 50 mg of sildenafil compared with placebo reduced orgasm latency and increased subjective arousal in those having the lowest vaginal pulse amplitude percentage change.16 In a fourth trial involving asymptomatic premenopausal women, a sildenafil-placebo crossover reported increased arousal and orgasm function.17 Case reports18 and open-label studies19 have also suggested efficacy for phosphodiesterase type 5 inhibitor treatment of women with sexual dysfunction associated with SRI treatment. The objective of our current trial was to use a protocol—similar to our previous RCT11 involving men with sexual dysfunction associated with SRI treatment—to assess the efficacy of sildenafil in the treatment of women, specifically women whose major depressive order is in remission while taking a stable dose of SRI antidepressants and who did not have a preexisting sexual dysfunction but due to the treatment had sexual dysfunction manifest as dysfunction of orgasm (delay) or arousal (lubrication).5 Recognizing the importance of the hormonal variability on nitric oxide signaling in sexual function in women20 and depression on hypothalamic-pituitary–adrenal axis regulation,21 we also examined endocrine measures. The following were our specific aims: (1) to compare the efficacy of sildenafil with placebo for treatment of sexual dysfunction associated with SRI treatment in women with remitted major depressive disorder; (2) to determine whether sildenafil treatment is associated with change in depression severity; and (3) to compare adverse events occurring with sildenafil and placebo treatment.

THE BIG “O” (OVERVIEW)

This prospective, parallel group, randomized, double-blind, placebo-controlled, 8-week trial to test the efficacy of a flexible dose of between 50 mg and 100 mg of sildenafil for sexual dysfunction in women was conducted from September 2003 to January 2007, at 7 US outpatient clinic medical centers. Each center's institutional review board approved the protocol.

Product	Dosage	Quantity + Bonus	Price
Kamagra	100mg	120 + 6 Pills	330.74€ 314.99€	Buy
Viagra Generic	100mg	60 + 4 Pills	96.36€ 91.77€	Buy
Viagra Generic	25mg	60 + 4 Pills	71.99€ 68.56€	Buy
Viagra Generic	25mg	120 + 6 Pills	125.56€ 119.58€	Buy
Kamagra Soft Tabs	100mg	272 + 12 Pills	593.42€ 565.16€	Buy
Kamagra Polo	100mg	272 + 12 Pills	622.94€ 593.28€	Buy
Viagra Generic	200mg	180 + 10 Pills	277.56€ 264.34€	Buy
Kamagra	100mg	32 Pills	121.24€ 115.47€	Buy
Viagra Generic	50mg	360 + 10 Pills	225.33€ 214.60€	Buy
Kamagra	100mg	60 + 4 Pills	201.34€ 191.75€	Buy
Viagra Generic	100mg	270 + 10 Pills	270.47€ 257.59€	Buy
Kamagra Oral Jelly	100mg	30 + 5 Sachets	136.20€ 129.71€	Buy

Before enrollment, each woman provided written informed consent to the investigator, who had explained the nature, purpose, and risks sildenafil 50mg tablet of the trial and who provided her with a copy of the information sheets. The study received an investigational new drug approvable letter from the FDA. Women were eligible if they (1) were between 18 and 50 years, (2) were premenopausal, (3) had a diagnosis of major depressive disorder in remission, (4) were taking an antidepressant with a selective or nonselective SRI mechanism for at least 8 weeks (at a stable dose for at least 4 weeks), and (5) were experiencing persistent sexual dysfunction for at least 4 weeks.

Country	Legal Status	Prescription Required	Notes
USA	Approved for certain uses	Yes	Off-label for women often not approved
UK	Prescription-only	Yes	Approved for male ED; off-label use in women
Canada	Restricted use	Yes	Prescription required; variable by province
Australia	Prescription-only	Yes	Limited clinical guidelines for women

Other eligibility criteria were good health, some form of regular sexual activity (ie, masturbation, oral sex, intercourse) at least twice monthly before the antidepressant treatment, willingness to continue efforts at sexual activity at least once weekly for the duration of the study, and satisfactory sexual function before onset of depression or antidepressant treatment.

• Sildenafil is often known by the brand name Viagra, primarily for men.
• Researchers are exploring other PDE5 inhibitors for women’s sexual health.
• Efficacy of sildenafil in women might depend on underlying health conditions.
• Women with cardiovascular issues should be particularly cautious with sildenafil.
• Some women report increased sexual satisfaction after using sildenafil.
• Medical advice is crucial before women consider sildenafil as a treatment.

In addition, any prior sexual dysfunction must have been limited to previous episodes of depression or antidepressant treatment and must have remitted on clinical improvement and discontinuation of medication. Major depressive disorder in remission was diagnosed according to Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV) criteria.22 Women had to score no more than 10 points on the Hamilton Rating Scale for Depression, which consists of 17 items that are clinician rated on a 5-point scale from 0 (absent) to 4 (severe).23 The remission threshold score of 10, rather than 7, was selected to adjust for sexual dysfunction associated with SRI treatment potentially inflating the score.24 In addition, women had to score no more than 10 on the Hamilton Rating Scale for Anxiety, indicating absence of significant symptomatic anxiety.25 Sexual dysfunction associated with SRI antidepressant treatment is defined by DSM-IV criteria for substance-induced sexual dysfunction,22 which includes impaired desire, arousal (lubrication), and orgasm and sexual pain.

• Sildenafil may help women with conditions like arousal disorder, but evidence varies.
• There is ongoing research into safe, effective female-specific doses of sildenafil.
• Side effects experienced by women can include dizziness, nausea, or visual disturbances.
• Consumption of alcohol while on sildenafil can increase side effect risks.
• Female sexual dysfunction can have psychological, hormonal, and physical causes.
• Sildenafil is not a cure-all; proper diagnosis is important for targeted treatment.

Women had to have substantial impaired sexual function defined by at least 1 of the following criteria that caused significant distress: (1) inability to have an orgasm (anorgasmia), according to the woman's opinion; (2) clinically significant orgasm delay with masturbation or intercourse that, according to the woman's opinion, represents a meaningful delay compared with her usual time to achieve orgasm in response to sexual stimulation before antidepressant medication interfered with her sexual function; or (3) inability to attain or maintain until completion of sexual activity an adequate lubrication or swelling response of sexual excitement that, according to the woman's opinion, interferes with her sexual function (compared with before taking antidepressant medication). Women were excluded for any of the following reasons: diagnosis of a sexual disorder other than one associated with SRI treatment or onset of major depressive disorder, genital anatomical deformity, hysterectomy with or without oophorectomy, and at least 6 months of established normal sexual function after the procedure and before onset of depression and antidepressant treatment, uncontrolled psychiatric disorder, diabetes mellitus, cardiovascular disease, alcohol or substance abuse or dependence, stroke, unstable cardiac condition, arrhythmia, or myocardial infarction within the last 6 months, current or anticipated use of nitrate or nitric oxide donor in any form, major relationship changes, proliferative retinopathy, investigational drug use within 3 months, current use of other therapies or medications to treat sexual dysfunction, a sexual partner who has or is receiving treatment for sexual dysfunction, or change in SRI antidepressant agent or prescribed dose during the study.

HOW TO GET YOUR PRESCRIPTION

How should sildenafil for women be used?

A Note on Gender and Sex Terminology

Additional exclusion criteria were use of hormone therapy; pregnancy; lactation; planning to become pregnant during the trial; of child-bearing potential and unwilling, unprepared, or judged unreliable to use an acceptable and verifiable form of contraception during the trial; Papanicolaou test results indicating further assessment; dyspareunia due to anatomical, inflammatory, infection condition, or clinical estrogen deficiency; amenorrhea over 1 year; or situational sexual dysfunction. Women were recruited and enrolled from outpatient settings, newspaper advertisements, postings, and referrals.

What special dietary instructions should I follow?

They were randomized to receive 1 of 3 treatments: 25 mg or 50 mg of sildenafil or placebo.14 A protocol-specified trial involved premenopausal or postmenopausal women with sexual arousal disorder without concomitant hypoactive sexual desire disorder. Women with low baseline estrogen and androgen levels received therapy, so their hormone levels would be within the range of normal therapy and were randomly assigned to receive either a flexible dose of between 25 mg and 100 mg of sildenafil or placebo.15 In a third trial, postmenopausal women receiving estrogen hormone therapy and who had acquired sexual arousal disorder and impaired orgasm found that a single dose of 50 mg of sildenafil compared with placebo reduced orgasm latency and increased subjective arousal in those having the lowest vaginal pulse amplitude percentage change.16 In a fourth trial involving asymptomatic premenopausal women, a sildenafil-placebo crossover reported increased arousal and orgasm function.17 Case reports18 and open-label studies19 have also suggested efficacy for phosphodiesterase type 5 inhibitor treatment of women with sexual dysfunction associated with SRI treatment. The objective of our current trial was to use a protocol—similar to our previous RCT11 involving men with sexual dysfunction associated with SRI treatment—to assess the efficacy of sildenafil in the treatment of women, specifically women whose major depressive order is in remission while taking a stable dose of SRI antidepressants and who did not have a preexisting sexual dysfunction but due to the treatment had sexual dysfunction manifest as dysfunction of orgasm (delay) or arousal (lubrication).5 Recognizing the importance of the hormonal variability on nitric oxide signaling in sexual function in women20 and depression on hypothalamic-pituitary–adrenal axis regulation,21 we also examined endocrine measures. The following were our specific aims: (1) to compare the efficacy of sildenafil with placebo for treatment of sexual dysfunction associated with SRI treatment in women with remitted major depressive disorder; (2) to determine whether sildenafil treatment is associated with change in depression severity; and (3) to compare adverse events occurring with sildenafil and placebo treatment. This prospective, parallel group, randomized, double-blind, placebo-controlled, 8-week trial to test the efficacy of a flexible dose of between 50 mg and 100 mg of sildenafil for sexual dysfunction in women was conducted from September 2003 to January 2007, at 7 US outpatient clinic medical centers.

Sexual Health in the Neurogenic Patient

Each center's institutional review board approved the protocol. Before enrollment, each woman provided written informed consent to the investigator, who had explained the nature, purpose, and risks sildenafil 50mg tablet of the trial and who provided her with a copy of the information sheets. The study received an investigational new drug approvable letter from the FDA. Women were eligible if they (1) were between 18 and 50 years, (2) were premenopausal, (3) had a diagnosis of major depressive disorder in remission, (4) were taking an antidepressant with a selective or nonselective SRI mechanism for at least 8 weeks (at a stable dose for at least 4 weeks), and (5) were experiencing persistent sexual dysfunction for at least 4 weeks. Other eligibility criteria were good health, some form of regular sexual activity (ie, masturbation, oral sex, intercourse) at least twice monthly before the antidepressant treatment, willingness to continue efforts at sexual activity at least once weekly for the duration of the study, and satisfactory sexual function before onset of depression or antidepressant treatment.

Vyleesi (bremelanotide)

In addition, any prior sexual dysfunction must have been limited to previous episodes of depression or antidepressant treatment and must have remitted on clinical improvement and discontinuation of medication. Major depressive disorder in remission was diagnosed according to Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV) criteria.22 Women had to score no more than 10 points on the Hamilton Rating Scale for Depression, which consists of 17 items that are clinician rated on a 5-point scale from 0 (absent) to 4 (severe).23 The remission threshold score of 10, rather than 7, was selected to adjust for sexual dysfunction associated with SRI treatment potentially inflating the score.24 In addition, women had to score no more than 10 on the Hamilton Rating Scale for Anxiety, indicating absence of significant symptomatic anxiety.25 Sexual dysfunction associated with SRI antidepressant treatment is defined by DSM-IV criteria for substance-induced sexual dysfunction,22 which includes impaired desire, arousal (lubrication), and orgasm and sexual pain. Women had to have substantial impaired sexual function defined by at least 1 of the following criteria that caused significant distress: (1) inability to have an orgasm (anorgasmia), according to the woman's opinion; (2) clinically significant orgasm delay with masturbation or intercourse that, according to the woman's opinion, represents a meaningful delay compared with her usual time to achieve orgasm in response to sexual stimulation before antidepressant medication interfered with her sexual function; or (3) inability to attain or maintain until completion of sexual activity an adequate lubrication or swelling response of sexual excitement that, according to the woman's opinion, interferes with her sexual function (compared with before taking antidepressant medication). Women were excluded for any of the following reasons: diagnosis of a sexual disorder other than one associated with SRI treatment or onset of major depressive disorder, genital anatomical deformity, hysterectomy with or without oophorectomy, and at least 6 months of established normal sexual function after the procedure and before onset of depression and antidepressant treatment, uncontrolled psychiatric disorder, diabetes mellitus, cardiovascular disease, alcohol or substance abuse or dependence, stroke, unstable cardiac condition, arrhythmia, or myocardial infarction within the last 6 months, current or anticipated use of nitrate or nitric oxide donor in any form, major relationship changes, proliferative retinopathy, investigational drug use within 3 months, current use of other therapies or medications to treat sexual dysfunction, a sexual partner who has or is receiving treatment for sexual dysfunction, or change in SRI antidepressant agent or prescribed dose during the study. Additional exclusion criteria were use of hormone therapy; pregnancy; lactation; planning to become pregnant during the trial; of child-bearing potential and unwilling, unprepared, or judged unreliable to use an acceptable and verifiable form of contraception during the trial; Papanicolaou test results indicating further assessment; dyspareunia due to anatomical, inflammatory, infection condition, or clinical estrogen deficiency; amenorrhea over 1 year; or situational sexual dysfunction. One canada sildenafil hundred forty-five patients were assessed for eligibility at screening (Figure). In addition to an assessment of medical history with detailed sexual history and recording of last menstrual period, all patients received a physical examination including blood pressure, 12-lead electrocardiogram, standard biochemistry and hematological laboratory tests, and pelvic examination with Papanicolaou test (unless documented within the last 12 months). Blood samples for determination of plasma concentrations of free testosterone, thyroid-stimulating hormone, tetraiodothyronine thyroxin, follicle-stimulating hormone, luteinizing hormone, cortisol, progesterone, estradiol, sex hormone–binding globulin, total testosterone, and prolactin were collected at the first and eighth week before 11 AM on days 1 to 10 of the menstrual period. Using SPSS version 10 (SPSS Inc, Chicago, Illinois), an unrestricted, computer-generated randomization schedule was developed by the study statistician (S.P.) and given to the independent pharmacy. The randomization assigned 49 patients to receive active sildenafil and 49 to receive identical placebo. The only restriction to this randomization was that the groups be of equal size. The largest difference in numbers assigned to the 2 groups at any point in the trial was 4 (excludes completions).

Methods and Objectives

A urine pregnancy test was administered to all women of childbearing potential at each visit. Investigators monitored, collected, and followed up on any spontaneous reports of adverse events, and they assessed and categorized the severity of the events and their relationship to the study drug throughout the trial.

What side effects can low dose sildenafil cause?

Similar content being viewed by others

At baseline, patients were allocated to the next available number that randomly assigned them to receive sildenafil or matching placebo (50-mg starting dose). Medications were sealed in sequentially numbered identical containers according to allocation sequence, and all study personnel and participants were blinded to treatment assignment for the duration of the study.

• The market for female sexual enhancement drugs is growing, including sildenafil research.
• Women should be aware of potential drug interactions when using sildenafil.
• Female sexual health involves multiple factors, not just blood flow.
• Sildenafil may not be effective for all women due to physiological differences.
• Regular follow-up with healthcare providers can optimize treatment and safety.
• Lifestyle factors such as stress and hormonal balance influence female libido.

Patients were instructed to take 1 tablet of trial medication approximately 1 to 2 hours before anticipated sexual activity, not more than once daily over the 8-week trial period and were required to make at least 1 attempt but were asked to try to make at least 2 attempts at sexual activity per week. The dose of study drug could be adjusted from 1 (50 mg) to 2 (100 mg) tablets based on investigator judgment of efficacy and tolerability, including the recording of the findings that resulted in any study drug dosage change and adverse events. Patients were given diaries with instructions for sildenafil 50 mg tab recording trial medication use and sexual activity. Sildenafil and placebo were provided by Pfizer Inc, New York, New York. Drug accountability, concomitant antidepressant treatment, vital signs, and self-rated and physician-rated symptom reports were assessed at each visit (weeks 2, 4, and 8), which included diary review and return of unused medication. A urine pregnancy test was administered to all women of childbearing potential at each visit. Investigators monitored, collected, and followed up on any spontaneous reports of adverse events, and they assessed and categorized the severity of the events and their relationship to the study drug throughout the trial.

DARE to PLAY Sildenafil Cream

Women were recruited and enrolled from outpatient settings, newspaper advertisements, postings, and referrals. One canada sildenafil hundred forty-five patients were assessed for eligibility at screening (Figure). In addition to an assessment of medical history with detailed sexual history and recording of last menstrual period, all patients received a physical examination including blood pressure, 12-lead electrocardiogram, standard biochemistry and hematological laboratory tests, and pelvic examination with Papanicolaou test (unless documented within the last 12 months). Blood samples for determination of plasma concentrations of free testosterone, thyroid-stimulating hormone, tetraiodothyronine thyroxin, follicle-stimulating hormone, luteinizing hormone, cortisol, progesterone, estradiol, sex hormone–binding globulin, total testosterone, and prolactin were collected at the first and eighth week before 11 AM on days 1 to 10 of the menstrual period. Using SPSS version 10 (SPSS Inc, Chicago, Illinois), an unrestricted, computer-generated randomization schedule was developed by the study statistician (S.P.) and given to the independent pharmacy.

Vyleesi (Bremalontide)

The randomization assigned 49 patients to receive active sildenafil and 49 to receive identical placebo. The only restriction to this randomization was that the groups be of equal size. The largest difference in numbers assigned to the 2 groups at any point in the trial was 4 (excludes completions). At baseline, patients were allocated to the next available number that randomly assigned them to receive sildenafil or matching placebo (50-mg starting dose). Medications were sealed in sequentially numbered identical containers according to allocation sequence, and all study personnel and participants were blinded to treatment assignment for the duration of the study.

Corresponding author

Patients were instructed to take 1 tablet of trial medication approximately 1 to 2 hours before anticipated sexual activity, not more than once daily over the 8-week trial period and were required to make at least 1 attempt but were asked to try to make at least 2 attempts at sexual activity per week. The dose of study drug could be adjusted from 1 (50 mg) to 2 (100 mg) tablets based on investigator judgment of efficacy and tolerability, including the recording of the findings that resulted in any study drug dosage change and adverse events. Patients were given diaries with instructions for sildenafil 50 mg tab recording trial medication use and sexual activity. Sildenafil and placebo were provided by Pfizer Inc, New York, New York. Drug accountability, concomitant antidepressant treatment, vital signs, and self-rated and physician-rated symptom reports were assessed at each visit (weeks 2, 4, and 8), which included diary review and return of unused medication.